Osteopontin in diabetic nephropathy: signpost or road?
Defining the molecular pathogenesis of diabetic nephropathy remains a huge challenge to the medical research community. Recent studies of knockout mice have provided new insights into the role of osteopontin in the pathogenesis of diabetic nephropathy.
Heuer
Josef G
JG
Eli Lilly and Company, Biotherapeutics Discovery Research, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. jheuer@lilly.com
Breyer
Matthew D
MD
D000419:Albuminuria / Q000188:drug therapy / Q000209:etiology; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D051379:Mice; D053495:Osteopontin / Q000378:metabolism*; D045162:Thiazolidinediones / Q000627:therapeutic use
D045162:Thiazolidinediones; D053495:Osteopontin